Engineering PEG10 assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination

Ruijing Tang[1,2,3,5], Luobin Guo[1,2,3,5], Tingyu Wei[1,2,3], Tingting Chen[1,2,3], Huan Yang[1,2,3], Honghao Ye[1,2,3], Fangzhou Lin[1,2,3], Yongyi Zeng[1,2,3], Haijun Yu[4], Zhixiong Cai[1,2,3,*], and Xiaolong Liu[1,2,3,*]

1 The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China;

2 The Liver Center of Fujian Province, Fujian Medical University, Fuzhou 350025, P. R. China;

3 Mengchao Med-X Center, Fuzhou University, Fuzhou 350025, P. R. China;

4 State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P. R. China;

5 These authors contributed equally: Ruijing Tang, Luobin Guo.

*Correspondence: Xiaolong Liu (xiaoloong.liu@gmail.com, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China); Zhixiong Cai (caizhixiong1985@163.com, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China)

Abstract

Tumor neoantigen peptide vaccines hold potential for boosting cancer immunotherapy, yet efficiently co-delivering peptides and adjuvants to antigen-presenting cells in vivo remains challenging. Virus-like particle (VLP), which is a kind of multiprotein structure organized as virus, can deliver therapeutic substances into cells and stimulate immune response. However, the weak targeted delivery of VLP in vivo and its susceptibility to neutralization by antibodies hinder their clinical applications. Here, we firstly designed a novel protein carrier using the mammalian-derived capsid protein PEG10, which can self-assemble into endogenous VLP (eVLP) with high protein loading and transfection efficiency. Then, an engineered tumor vaccine, named ePAC, was developed by packaging genetically encoded neoantigen into eVLP with further modification of CpG-ODN on its surface to serve as an adjuvant and targeting unit to dendritic cells (DCs). Significantly, ePAC can efficiently target and transport neoantigens to DCs, and promote DCs maturation to induce neoantigen-specific T cells. Moreover, in mouse orthotopic liver cancer and humanized mouse tumor models, ePAC combined with anti-TIM-3 exhibited remarkable antitumor efficacy. Overall, these results support that ePAC could be safely utilized as cancer vaccines for antitumor therapy, showing significant potential for clinical translation.

Introduction

Neoantigens, originating from non-synonymous mutations, incomplete splicing, translation of alternatives, or posttranslational modifications, are highly immunogenic because they are absent in normal tissues and can evade central thymic tolerance mechanisms(Schumacher et al., 2019). Hence tumor neoantigen vaccines have been demonstrated as a promising and safe strategy in the treatment of various solid tumors (Ott et al., 2017; Cai et al., 2021; Chen et al., 2022). Typically, neoantigen peptides mixed with adjuvants are formulated into tumor neoantigen vaccines and directly administered to patients. Upon uptake of these antigen peptides and adjuvants, dendritic cells (DCs) are stimulated to activate neoantigen-specific $CD8^+$ T cells, which in turn eliminate tumor cells and impede tumor progression (Li et al., 2017; Ott et al., 2017). However, the free antigen peptides and adjuvant inside the body following systemic administration tend to experience the rapid clearance and enzymatic degradation that would significantly limit their antitumor efficacy.

Lentiviruses offer an excellent approach to cross cell membranes by interacting with specific host cell receptors through viral envelope glycoproteins (Sundquist et al., 2012). To ensure safe gene delivery without permanent integration into the human genome, the protein of interest (POI) is always directly fused to lentiviral structural proteins for transduction (Voelkel et al., 2010; Kaczmarczyk et al., 2011; Cai et al., 2014). Specifically, the POI can be inserted into the C-terminal of matrix protein (MA), core capsid (CA), nucleocapsid (NC), or even integrase (IN) with a protease site, allowing for independent functions upon cleavage by viral protease (Voelkel et al., 2010). For example, in the delivery of CRISPR-Cas9 ribonucleoproteins (RNP), the lentiviral gag domain, including MA and NC, were fused with Cas9 and mixed with the full-length gag-pol domain for virus-like particle (VLP) packaging; upon transfection, Cas9 was cleaved by the protease from the viral pol domain in the host cell, leading to excellent gene editing efficiency (Mangeot et al., 2019; Hamilton et al., 2021; An et al., 2024; Hamilton et al., 2024). To enhance the delivery efficacy of VLP,

the ratio between gag-POI and gag-pol should be optimized. Additionally, the cleavage linker between gag and POI is also crucial for transfection, as it should be exposed on the protein surface for effective recognition by protease (Banskota et al., 2022; Raguram A 2022; An et al., 2024). In addition to nuclease delivery by lentiviral-designed VLP, gag domain from human immunodeficiency virus (HIV), adeno-associated virus, Hepatitis B virus (HBV), Hepatitis C virus (HCV), or bacteriophages MS2, can also be assembled into VLP to carry other specific antigens to form VLP-based vaccines (Roldão A 2010; Klamp et al., 2011; Li et al., 2014). With sizes ranging from 20 to 200 nm, resembling pathogen-associated structural patterns, these VLP-based vaccines can efficiently elicit in vivo immune responses and have been approved for use in clinical trials(Roldão A 2010). Immune cells such as dendritic cells (DCs) and macrophages take up these vaccines through phagocytosis and micropinocytosis, and the present antigens from VLP to stimulate T cells for treating infectious diseases or cancer. However, viral-derived gag-pol in VLP, as a heterologous protein with strong immunogenicity, can also stimulate B cells to secrete neutralizing antibodies. These antibodies may remove VLPs from the body, thereby inhibiting the efficacy of VLP-based vaccines (Nooraei et al., 2021).

PEG10 is a domesticated transposable element, which is expressed in mammals encoding two open read frames, PEG10-RF1(a gag-like protein) and PEG10-RF1/2 (a fusion of the gag and pol domains) (Lux et al., 2005). In brain, PEG10 has been identified as a component of stress granules and extracellular vesicles responsible for carrying mRNAs and proteins to transport information between cells (Pandya et al., 2021). Overexpression of PEG10 in HEK293FT cells resulted in the observation of extracellular vesicles containing the core capsid (CA) domain in the culture medium, demonstrating that endogenous retrovirus-like gag protein could be engineered into VLP for molecule transport (Segel M et al., 2021). Beside PEG10, the retrovirus-like protein Arc can also form VLP for cell communication, which is smaller than PEG10 (Ashley et al., 2018; Pastuzyn et al., 2018). Therefore, theoretically, endogenous retrovirus-like gag protein could be fused with antigens to produce VLP-based

vaccines. However, endogenous VLP (eVLP) lack immunogenicity compared to viral VLP. This means that eVLP alone may struggle to activate dendritic cells (DCs) for inducing a robust immune response. To address this limitation, synthetic CpG oligonucleotide (CpG-ODN), a Toll-like receptor 9 (TLR9) agonist, has been explored as adjuvants in clinical vaccine trials due to their potent immunostimulatory properties(Coffman et al., 2010). DEC-205 is a multi-lectin receptor that has the binding capacity to CpG-ODN. For DCs, once CpG-ODN bonds to DEC-205, pinocytosis will be activated (Lahoud et al., 2012). Once CpG-ODN is connected to eVLP, the particles will further gain two advantages: first, CpG-ODN modified eVLP tend to bind DEC-205, for initiating DCs to engulf these particles; second, after endocytosis, the CpG-ODN can enhance DC maturation and antigen presentation as an adjuvant. Therefore, CpG-ODN modification represents an excellent strategy to improve immune responses for eVLP-based vaccines.

In order to overcome the challenges associated with peptide vaccine delivery and leverage the unique biological characteristics of PEG10, herein we firstly engineered PEG10 gag domain with liver cancer specific neoantigens or HBV antigens to assemble into eVLP for peptide vaccine delivery. Furthermore, CpG-ODN was anchored on the surface of eVLP-antigen complex, named as ePAC to enhance the DC targeting efficacy and the antigen induced immune response. In vivo studies we further evaluated the antitumor effect of our ePAC in hepatocellular carcinoma (HCC) mouse model and confirmed that ePAC, as a cancer therapeutic vaccine, can activate immune response and regulate the tumor microenvironment. In general, our study reported a novel antigen delivery system which shows remarkable efficacy in transporting antigens to develop cancer therapeutic vaccine.

Results

Preparation and Characterization of PEG10-assembled eVLP

The protein transfection process relying on VLP produced by virus-associated gag domain is straightforward and highly efficient (Voelkel et al., 2010; Kaczmarczyk et

al., 2011). As a type of retrovirus-like protein, mammalian-derived PEG10 possesses the canonical gag domain. We envision that the Protein of Interest (POI) could be fused to the PEG10 gag domain to create endogenous Virus-Like Particle (eVLP), which could then be delivered to targeted cells. To assess the transfection feasibility, eGFP was fused to the PEG10 gag domain behind the putative cutting site (NSQTD*PTEPV)(Lux et al., 2005) or a GS linker, along with the PEG10 gag-pol domain (Figure 1A). Plasmid VSVg is commonly used to assist retrovirus transfection. Therefore, as shown in Figure 1B, gag-eGFP or gag-pol-eGFP combining with VSVg were transfected to HEK293T cells for eVLP production. After 24 hours, the fluorescence from HEK293T cells were recorded (Figure. S1A). We observed that eGFP fused behind the gag domain showed superior expression level compared to the gag-pol fused structure. Therefore, we chose group 2 to further determine the secreted eVLP, which were collected from the supernatant of the transfected HEK293T cells and concentrated through ultracentrifugation. As show in Supplementary Figure 1B and 1C, gag-eGFP protein was detectable via western blot analysis in the concentrated supernatant, similar to its detection in cell lysate, with CD9 serving as the loading control (the maker of extracellular vesicles (Boker et al., 2018)). These results indicated that gag-eGFP could be self-assembled into eVLP for collection.

Subsequently, the eVLPs collected from the four groups in Figure S1A were transfected into fresh HEK293T cells. Encouragingly, all gag and eGFP fused structure exhibited fluorescence in the cells, even with efficiency 90.1% by GS linker (Figure 1C). For cutting site connecting structure, it reduced to 85.2% possibly owing to the steric effect from the fused protein during gag domain accumulation in cellular membrane (Figure 1C). Meanwhile, the transfected HEK293T cells were collected and analyzed by Western Blot. The results further confirmed that eGFP can be transfected into HEK293T cells through PEG10 gag domain packaged eVLP (Figure 1D). Furthermore, when eGFP was fused to full-length PEG10, the fluorescence intensity was lower compared to the gag-only fusion type. But two distinct bands can still be observed during blotting, indicating successful self-cleavage by PEG10

protease domain (Figure 1C and 1D). These results pointed out that GS linker could assist gag domain accumulation after fusing POI, and co-packaging PEG10 pol domain could facilitate POI releasing from gag domain in the presence of cutting site. Thus, behind cutting sequence of PEG10 gag domain, we used GS linker to connect POI for following experiments, presenting as gag-POI.

Normally, gag-pol and gag-POI should be co-transfected to produce VLP. Increasing the percentage of gag-pol could make VLP more stable and release POI efficiently from gag domain, however, it also would reduce the loading capacity of VLP (Hamilton et al., 2021; Banskota et al., 2022). Thus, to carry sufficient targeting protein for transfection, the plasmid ratio between gag-pol and gag-POI should be coordinated. We then compared eVLP transfection efficiency to HEK293T cells with various ratios of gag-pol and gag-eGFP plasmids, and noticed that gag-pol 2 μg: gag-eGFP 14 μg: VSVg 3 μg was the most appropriate for targeting protein transfection (Figure 1E and 1F). Meanwhile, the function of VSVg for PEG10 based eVLP transfection was also determined. Without VSVg, the positive eGFP cells decreased dramatically from 73.5% to 16.4%, indicating that eVLP, like lentiviral or retroviral vectors, needed VSVg for transfection (Figure 1G and 1H). To sum up, we designed a new protein transfection strategy based on PEG10-packaged eVLP with high transfection efficiency.

Envelope decoration of neoantigen-loaded eVLP

To prepare eVLP-based neoantigen vaccine, PEG10 gag domain was then fused with 7 tumor neoantigens from Hepa1-6 cell line (Chen et al., 2022) instead of eGFP, and the productivity of eVLP was evaluated by quantifying the total amount of proteins produced from one 10-cm dish of transfected HEK293T cells (eVLP vs control: 212±7.388 μg vs 76.59±7.463 μg) (Figure S2). But in vivo, solely relying on the eVLP-antigen complex for antigen delivery to antigen-presenting cells (APCs) and immune response activation is not efficient. Although pseudotyped vectors expressing VSVg demonstrate robust mechanical stability and high titers for in vitro transduction,

achieving effective transduction efficiencies for therapeutically relevant cells in vivo, such as hematopoietic stem cells, dendritic cells (DCs), and T cells, requires further modification of the vector surface by antibodies, peptides, or nucleotides (Lahoud et al., 2012; Lynn et al., 2020; Wei Y 2021). Here we utilized CpG-ODN to modify the eVLP-antigen complex, resulting in what we termed ePAC, which can interact with the DC surface protein DEC-205, thereby stimulating the intracellular receptor TLR9 and enhancing DC maturation. The modification process involved two steps: 1) The free amino group from the concentrated eVLP was reacted with NHS Ester carried by DBCO under 4℃ for 12h in PBS buffer. This step allowed for the anchoring of DBCO onto the eVLP. 2) CpG-ODN synthesized with 3'Azide (and 5'FAM) was added to DBCO anchored eVLP. This facilitated copper-free click chemistry, enabling the coupling of CpG-ODN to the eVLP (Figure 2A). Furthermore, by varying the concentration of DBCO-C6-NHS Ester, ePAC exhibited different CpG-ODN loading efficiency as evidenced by agarose gel electrophoresis (Figure 2B). Meanwhile, ePACs with elevated levels of CpG-ODN modification demonstrated robust fluorescent intensity in flow cytometry analysis (Figure 2C).

DEC-205 is a CpG-ODN receptor expressed by a variety of antigen presenting cells (Lahoud et al., 2012; Li et al., 2021). To explore the potential binding of CpG-ODN by DEC-205 and its impact on enhancing ePAC transfection efficiency, CHO cells, known for their ease of engineering to express large functional membrane proteins, were utilized to express mouse DEC-205. By flow cytometry analysis, ePAC transfection efficiency was 39.70±2.157 % in CHO cells with transient transfected DEC-205, which was significantly, higher than that in wild type CHO cells (29.0 ± 1.514%, $p=0.0035$) (Figure 2D and 2E). In addition to transient expression, DEC-205 fused with mCherry at the C-terminal was introduced into CHO cells via lentiviral transfection. The expression of DEC-205-mCherry was notably observable using mCherry fluorescence under confocal microscopy (Figure 2F). Meanwhile, following a 2-hour co-culture with ePAC, CHO cells expressing DEC-205-mCherry exhibited stronger FAM signal than that in wild type CHO cells (Figure 2F). These results

suggested that CpG-ODN decoration could specifically improve the eVLP transfection efficiency in cells expressing DEC-205.

In vitro stimulation of DCs by ePAC

The transfection efficiency of ePAC was further verified in DC2.4 cells and bone marrow-derived dendritic cells (DCs) from mouse (Figure 3A and 3B). With CpG-ODN modification, the transfection efficiency of eVLP for DC2.4 cells and DCs were 99.9% and 43.4%, respectively (Figure 3C and 3D). To confirm whether ePAC activated the intercellular receptor TLR9 signaling with cytokines secretion, the medium from DC2.4 cells were analyzed by ELISA. Compared to CpG-ODN or eVLP treated group, ePAC could significantly upregulate IL-6 and IL-12p70 secretion (Figure 3E). Furthermore, the DC2.4 cells were also collected for Western Blot to analyze TLR9-Myd88-P65 signaling. After 6h stimulation, ePAC treated group exhibited higher fold change ratio of phosphorylated P65 (0.79 vs 0.34) and Myd88 (0.63 vs 0.37) than eVLP group (Figure 3F). These results suggested that ePAC can be uptake by DC2.4 cells efficiently to activate the intracellular TLR9 signaling. To further investigate the immune response triggered by ePAC stimulated APCs in vitro, moused bone marrow derived DCs were co-culture with ePAC for two days. Subsequently, the expression levels of CD80 and CD86 (the hallmarks of DCs maturity) in $CD11c^{+}$ DCs were measured by flow cytometry. In contrast to eVLP treated group, the ePAC treated group showed a significant increase in CD80 and CD86 expression (24.08±0.2355% vs 14.25±0.7854%) (Figure 3G and 3H). Following this, mouse spleen-derived T cells were stimulated in vitro by the ePAC-transfected DCs for two days. On the third day, the fresh transfected DCs were reintroduced to the stimulated T cells for an additional two rounds of co-culture. Hepa1-6 cells were then co-cultured with the final activated T cells for 3 days to assess the killing efficiency mediated by DC-activated T cells. Post-co-culture, the cell culture supernatant was collected for cytotoxicity assays using LDH detection (Figure 3B). Notably, we found the percentage of Hepa1-6 cell death was dramatically increased in ePAC treated group (ePAC 57.73±1.018% vs eVLP 39.49±0.08%),

similar with the positive control treated with Hepa1-6-derived neoantigen peptides plus CpG-ODN (Figure 3I). Together, our data suggested that ePAC is capable of delivering neoantigens to DCs for enhancing T cell-mediated antitumor activity.

ePAC delivery and immune activation in vivo

The migration of ePAC to lymph nodes and its capacity to activate DCs are crucial determinants of the quality of the induced immune response. In order to investigate the accumulation of ePAC in lymph nodes, it was initially labeled with Dil and then subcutaneously injected into C57BL/6 mice (Figure 4A), while Dil and Dil plus eVLP (only carrying neoantigens) served as the control groups. As shown in Figure 4B, both ePAC and eVLP with the same vesicle structure produced from 293T cells, can efficiently accumulate in the draining lymph nodes two days post injection. The accumulation level of ePAC in lymph node is approximately 1.5 times higher than that of Dil plus eVLP group, and 5 times higher than that of Dil only group (Figure 4C). Subsequently, the collected lymph nodes were digested to prepare single-cell suspensions, and flow cytometry was employed to quantify the cellular uptake of ePAC in $CD11c^+$ cells. As shown in Figure 4D and 4E, CpG-ODN modification enhanced the uptake efficiency of eVLP (ePAC 12.57±0.4055% vs eVLP 9.29±0.7225%, $p=0.0391$) compared to eVLP without CpG-ODN in vivo. To further determine the immune responses, the mice were subcutaneously injected with CpG-ODN, eVLP or ePAC for three times at different time points (Figure 4C). After sacrifice, the upregulation of MHC-II, CD80 and CD86 in $CD11c^+$ DCs from lymph nodes was measured by flow cytometry. In comparison to eVLP treated group, the ePAC treated group exhibited significantly higher expression of MHC-II (ePAC 62.03±0.7753 vs eVLP 48.30±3.251, $p=0.0093$) and co-expression of CD80 and CD86 (ePAC 24.77±0.2333 vs eVLP 17.07±0.5239, $p=0.0023$) in $CD11c^+$ DCs, indicating superior activation of DC maturation (Figure 4G-4J). Moreover, to analyze the formation of memory T cells induced by ePAC, the mouse splenic T cells were reactivated by DCs in vitro for interferon (IFN)-γ ELISPOT assay. The secretion of IFN-γ by T cells from ePAC stimulated group was approximately 2 times higher than

that of eVLP treated group, (ePAC 156±13.45 vs eVLP 74±13.87, *p=0.0011*, Figure 4K and 4L). These results indicated that ePAC can be uptake by lymph nodes to activate DCs and T cells, thus holding significant potential as therapeutic vaccines.

Antitumor effect of ePAC in subcutaneous HCC model

The therapeutic efficacy of ePAC was assessed in C57BL/6 mice bearing Hepa1-6 tumor cells. A total of thirty mice with tumors of approximately 60 mm^3 were randomly divided into five groups (n=6 per group). These groups were subcutaneously injected with PBS, CpG-ODN, eVLP, eVLP + CpG-ODN and ePAC, respectively, on the day 0, day 4, and day 8 (Figure 5A). Mice treated with PBS exhibited rapid tumor growth, whereas tumor growth in the other treatment groups significantly slowed down after three injections, and only tumors in ePAC treated group began to shrink after 10 days of treatment (Figure 5B and 5C). To further investigate whether ePAC exerted antitumor activity by activating immune responses, spleen and tumor samples were isolated from the treated mice. The percentage of effector memory T cells in the spleen was assessed via flow cytometry, revealing higher levels in the ePAC treated group (31.60±1.48%) compared to the eVLP group (14.22±1.377%) or the eVLP + CpG-ODN group (20.73±2.209%) (Figure 5D and 5E). Within the tumors, the infiltration of CD4 and CD8 T cells were examined using immunohistochemistry. While changes in CD4 T cells were not apparent across all groups, CD8 T cell infiltration was notably stimulated by ePAC (Figure 5F and 5G). The activation of the infiltrating CD8 T cells was further assessed by flow cytometry based on the expression level of 41-BB. As shown in Figure 5H and 5I, 4-1BB$^+$ CD8$^+$ T cells in total CD8$^+$ T cells of ePAC treated group were 64.9%, substantially higher than in other groups (7.0% in PBS treated group, 18.4% in CpG-ODN treated group, 9.94% in eVLP treated group, 41.1% in eVLP + CpG-ODN treated group). These results suggest that the ePAC is an effective tumor vaccine capable of efficiently eliciting antitumor immunity.

Normally, strong activation of CD8 T cells is often accompanied by high expression

levels of immune checkpoints, which can inhibit their antitumor function. Next, we compared the expression level of PD-1, TIM-3 and CTLA-4 in CD8 T cells from tumor tissues between PBS treated group and ePAC treated group. From the results of multicolor immunofluorescence, TIM-3 expression in ePAC treated group significantly increased (ePAC 45±5.568% vs PBS 8±2.082%, $p<0.0001$) (Figure 5J and 5K). These results indicated that further combining ePAC with TIM-3 antibody (αTIM-3) might improve the antitumor efficiency.

Enhancing ePAC antitumor efficacy in orthotopic HCC model by αTIM-3 combination

To accurately simulate the intrahepatic immune microenvironment and monitor vaccine response, we established an orthotopic hepatocellular carcinoma (HCC) model using Hepa1-6-luc-bearing mice. Given the upregulation of TIM-3 following ePAC vaccination, we aimed to enhance the antitumor immune response by combining ePAC with αTIM-3. The mice were randomly divided into 4 groups treated with PBS, αTIM-3, ePAC and ePAC + αTIM-3 (Figure 6A). As shown in Figure 6B, the combination of ePAC and αTIM-3 showed the lowest luciferase activity of tumors at the day 28, although the only αTIM-3 or ePAC treated mice showed reduced luciferase activity. Furthermore, the orthotopic tumor progress of 4/6 mice treated by ePAC + αTIM-3 was completely inhibited without any ghost, in contrast to the PBS (0/6), αTIM-3 (2/6), or ePAC treated alone (2/6) (Figure 6B). And the excellent synergistic therapeutic efficiency was further verified by the photograph of the liver and HE analysis (Figure 6C). To further investigate the changes in immune responses induced by the combination of ePAC and αTIM-3, we isolated the spleen and tumor from the treated mice. The effector memory $CD8^+$ T cells in spleen and the infiltration of $CD8^+$ T cells in tumor tissue were evaluated using flow cytometry. As shown in Figure 6D-6I, the percentages of effector memory $CD8^+$ T cells (ePAC + αTIM-3 14.35±1.168% vs ePAC 11.32±0.6404% vs αTIM-3 11.28±0.3341%) and the infiltrated $CD8^+$ T cells (ePAC + αTIM-3 55.72±2.733% vs ePAC 40.16±1.435% vs αTIM-3 37.79±2.278%) in mice treated with the combination of ePAC and αTIM-3

were higher than those in the other three groups . Additionally, the neoantigen-specific T cells from the infiltrated $CD8^+$ T cells in tumor tissues collected from the combined therapy group were significantly higher than that in the other treated groups (ePAC + αTIM-3 9.06±1.258% vs ePAC 4.50±0.7195% vs αTIM-3 0.89±0.0746%). These results confirmed that our vaccine can activate the antigen-specific immune responses to efficiently elicit antitumor effects, highlighting the promising potential of combining ePAC with αTIM-3 as a therapeutic strategy for hepatocellular carcinoma.

Antitumor effect by HLA-A*0201 restricted vaccine

To further confirm the function of T cell stimulation and antitumor effect of eVLP-packaged vaccine in human immune system, we incorporated an HBV-derived antigen (HBc18-27, with high binding affinity with HLA-A*0201) instead of previous neoantigens from Hepa 1-6 cells to PEG10 to prepare the ePAC vaccine. Peripheral blood mononuclear cells (PBMCs) from healthy donners with HLA-A*0201 restriction was used to derive monocytes, which were then induced with IL-4 and GM-CSF for 5 days to generate immature DCs (iDCs). Subsequently, the ePAC was added to stimulate iDC maturation for 2 days. T cells from the same doner's PBMCs with removing monocytes, were then co-cultured with the stimulated iDCs (Figure 7A). After three times of co-culture, the expression level of 4-1BB in T cells were significantly increased in ePAC treated group (ePAC 19.60±2.910% vs eVLP 8.367±2.485%) (Figure 7B). To evaluate whether the DC-activated T cells led to killing of HBV-infected tumor cells, we performed tumor killing assays against HepG2.2.15 cells with stable expression of HBV antigens and HLA-A*0201 (Figure 7A). The activated T cells were then transfer to the plates seeded with HepG2.2.15 one day before at the ratio of 10: 1. The time dependent co-culture state was recorded by microscopy. From the image and LDH assay, we found that ePAC could ultimately improve T cell-mediated killing of tumor cells (ePAC 51.08±5.087% vs eVLP 27.56±2.433%) (Figure 7C and 7D). These data suggested that human derived DCs could also be activated to present HLA-A*0201-restricted antigen by ePAC in vitro.

The therapeutic efficacy of ePAC was further evaluated on HLA-A*0201 transgenic mice bearing Hepa1-6 tumor cells. Hepa1-6 cells were infected with adenovirus to express HLA-A0201 and the HBc18-27 epitope prior to seeding in mice (Figure S3A). 48 hours post-infection in vitro, strong mCherry signals were observed in the cells under an MOI of 500, and the HLA-A*0201 was consistently expressed on the cell surface (Figure S3B and S3C), suggesting that adenovirus-infected Hepa1-6 cells could potentially be targeted by ePAC vaccine-activated T cells in HLA-A0201 transgenic mice. After inoculating Hepa1-6 cells, a total of fifteen mice with tumors of approximately 60 mm^3 were randomly divided into three groups and the time was recorded as day 0. These mice were subcutaneously injected with PBS, αTIM-3, and αTIM-3 + ePAC, respectively, on the day 0, day 4, and day 8 (Figure 7E). Two days before the treatment, the adenovirus carrying HBc18-27 and HLA-A*0201 were intratumorally injected to the tumors again to maintain the expression of HBc18-27 and HLA-A*0201. The mice inoculated with PBS and αTIM-3 suffered from continuous and rapid tumor growth, while in αTIM-3 + ePAC, tumor growth was significantly inhibited (Figure 7F and 7G). To further validate the immune response in tumors, the infiltrated $CD8^+$ T cells in the tumors was analyzed by flow cytometry, revealing a higher percentage in total CD3 positive cells from the αTIM-3 + ePAC treated group (18.0±0.7197% vs 11.96±0.4130%) than that from the only αTIM-3 treated group (Figure 7H and 7J). Additionally, the activated level of the infiltrated $CD8^+$ T cells were also tested based on the expression of 4-1BB. As shown in Figure 7I and 7K, there was a stronger activation level in the αTIM-3 + ePAC treated group (18.86±2.573%) compared to the αTIM-3 treated group (7.27±1.218%). Collectively, our data suggested that that ePAC, as tumor vaccine, can elicit antigen-specific immune responses in humanized mice with HLA-A*0201 restriction, highlighting its potential as an effective immunotherapeutic strategy for targeting HBV-associated tumors.

Discussion

Neoantigen vaccines designed by mixture of adjuvant and polypeptides have been

demonstrated to effectively inhibit tumor growth and metastasis in mouse model (Mandelboim O 1995), and successfully treated advanced melanoma in clinical studies (Ott et al., 2017; Sahin et al., 2017). Our previous study also demonstrated that this type of personalized neoantigen vaccine can effectively prevent recurrence of primary liver cancer after surgery (Cai et al., 2021). All these studies have proved the antitumor effect by neoantigen-induced immune responses. Different from polypeptide vaccines, here we used PEG10 gag domain to directly fuse with neoantigens to package ePAC as cancer vaccine. This formulation has several advantages compared to polypeptides. Firstly, we can link multiple neoantigens into one plasmid for direct expression and harvest it as lentivirus by ultracentrifugation, so vaccines can be prepared easily in laboratory. Secondly, the cost of synthesizing polypeptides greatly saved, and it also avoids the situation that some polypeptides with strong immunogenicity, but high hydrophobicity cannot be synthesized. In addition, eVLP is more stable than polypeptide, which is essentially a vesicle produced from HEK293T cells. Although we did not compare the antitumor efficiency between polypeptide and eVLP in vivo, eVLP packaged cancer vaccine really induced neoantigen specific CD8 T cells to antitumor. Therefore, we first demonstrate that PEG10 can co-express neoantigens and be packaged as eVLP-based cancer vaccine to induce strong immune response.

As a mammalian virus-like protein, PEG10 is the first to be developed to delivery mRNA and protein as eVLP (Abed et al., 2019; Pandya et al., 2021; Segel M et al., 2021). Arc is another endogenous virus-like protein with smaller amino acid length, mainly because it has lost functional protein domain during evolution and only retains the gag domain to support vesicle formation (Ashley et al., 2018; Pastuzyn et al., 2018). If Arc is engineered as eVLP, only two plasmids (gag-antigens and VSVg) are needed to prepare tumor vaccines, which could be simpler and more stable. But both PEG10 and Arc are mammalian homogenous proteins without the ability to induce host immune responses as natural viral proteins. And they also cannot specifically target to APC cells. In our study, CpG-ODN was anchored onto the surface of eVLP

to activate DCs and direct eVLP to target DCs in vivo. In addition to serving as an adjuvant and targeting DCs, CpG-ODN possesses other advantages. Firstly, its nucleic acid sequence is short and easy to synthesize, resulting in low costs. Secondly, CpG-ODN as adjuvant has been approved by FDA. Furthermore, CpG-ODN is easy to modify with functional groups during synthesis, allowing for efficient conjugation to the surface of VLPs via click chemistry reactions.

Although neoantigen vaccines can induce immune responses to efficiently inhibit the development of tumors, some problems have been discovered in our previous studies. The most typical one is the high expressing level of PD-1 and TIM-3 in T cells after vaccination. When we used αPD-1 or αTIM-3 for combined intervention, the antitumor effect was superiors than neoantigen vaccine only (Chen et al., 2022; Zhao et al., 2022; Lin et al., 2024). In this study, we also measured the exhausted CD8 T cells in subcutaneous tumors, and conducted the combined strategy with αTIM-3, which resulted in a more significant antitumor effect. Cytokines can also be used as a combined strategy for antitumor with neoantigen vaccines. IL-10 can reduce the exhaustion level of T cells through metabolic reprogramming (Guo et al., 2021; Zhao et al., 2024); IL-7 and IL-15 can moderately promote T cell proliferation and maintain the stemness of activated CD8 T cells (Adachi et al., 2018; Silva et al., 2019). Therefore, in the next step, we will continue to explore some combined strategies based on ePAC vaccines and develop more efficient antitumor strategies for clinical translation.

In summary, we genetically engineered PEG10, one of the mammalian retrovirus-like protein, to establish an eVLP vector for antigen polypeptide delivery. Using this strategy, we further designed CpG-ODN modified tumor vaccine ePAC, which can effectively accumulate in the lymph nodes for DC targeting and stimulation. Thus, following the antigen presentation and cytokine secretion by the DCs, the activation of the tumor antigen-specific immune response leaded to considerable inhibition of tumor growth. These findings shed light on fundamental studies of fusion-based cargo

delivery by eVLP, offering a promising avenue for the development of therapeutic vaccines targeting infectious diseases and cancers.

Materials and methods

Plasmids

PEG10 DNA sequence was synthesized according to pCMV-MmPeg10rc4 (addgene #174858). Then, the fragments of PEG10 including gag and gag-pol domain were amplified by PCR and inserted to pcDNA3.1 vector for plasmid construction. DEC205 was amplified by PCR from mouse bone marrow derived DCs, and mCherry was fused to the C-terminal of DEC205 and then inserted to pCDH vector for plasmid construction. Hepa1-6 cell derived seven neoantigens were identified in our previous study(Chen et al., 2022), and the DNA sequences were fused to the C-terminal of PEG10 gag domain cloned into pcDNA3.1 vector. The DNA sequence of HBc18-27 epitope was also synthesized and fused to PEG10. All DNA sequences were confirmed by sequencing after purification (EndoFree Maxi Plasmid Kit, TIANGEN Biotech). The sequences of these plasmids were listed in Table S1.

Cell lines

HEK293T cells, CHO cells, DC2.4 cells and Murine HCC cell line Hepa1-6 cells were obtained from ATCC. HepG2.2.15 cells were purchased from IMMOCELL (Xiamen, China). All these cells were cultured in DMEM containing 10% FBS and 1 % penicillin/streptomycin at 37 °C in a humidified environment with 5% CO2. Luciferase-expressing Hepa1-6 (Hepa1-6-luc) cells were established through lentivirus transfection expressing luciferase reporter gene, and then the positive cells were selected by puromycin and maintained in low concentration of puromycin (Shanghai Genechem Co., Ltd).

eVLPs production, purification and modification

eVLPs were produced by transient transfection of HEK293T cells. Briefly, HEK293T cells were seeded in 10-cm dish 24h before transfection. Then, the plasmids

expressing PEG10 (16 μg) and VSVg (3 μg) were co-transfected per dish. For PEG10, it includes two plasmids, gag-POI and gag-pol. The ratio between gag-POI and gag-pol was regulated according to different experiments as indicated. After 48 h and 72 h, the cell culture medium was collected and centrifuged at 2000 g for 20 min to remove cell debris. The clarified eVLP-containing supernatant was then filtered by a 0.45-μm PVDF filter (EMD Millipore, #SE1M003M00), and ultracentrifuged at 120,000 g for 1.5h at 4°C in a Beckman Coulter Optima XPN-80 ultracentrifuge. Afterwards, the supernatant was discarded, and the pellet that finally harvested from one 10-cm dish around 20 ml cell culture medium was then further resuspended by 200 μl PBS. For eVLP that were used in the following in vitro experiments, it was concentrated 100-fold from cell culture medium using Lenti-X™ Concentrator (Takara, #631231) according to the manufacturer's protocol. For eVLP that were injected into mice, it was concentrated 1000-fold by ultracentrifugation using a cushion of 20% (w/v) sucrose in PBS. To modify the concentrated eVLP by CpG-ODN, the DBCO-C6-NHS Ester (30 mg/ml, MACKLIN, China) was added into eVLP overnight at 4°C, then dialyzed using an ultra-centrifugal filter tube (Amicon® Ultra-0.5 50k device, Millipore, Darmstadt) extensively with PBS for three times. Afterwards, the CpG-ODN-Azide (100 μM, General Biol., China) was then further reacted with DBCO-eVLP through click chemistry at 37°C for 2h. Subsequently, the product was dialyzed again using an ultra-centrifugal filter tube against PBS for three times. The CpG-ODN modified eVLP was stocked at -80°C for further usage.

Adenovirus production

Adenovirus vectors were produced by transfecting HEK293A cells with transgenic transfer plasmid pDC315 and pBHGlox(delta)E1, 3Cre packaging plasmid in a 1:1 molar ratio, normalized to a total mass of 20 μg plasmid/10-cm dish of cells, incubated with 60 μl PEI in 500 μl Opti-MEM medium. After two weeks, the transfected cells were harvested using 1 mL PBS and lysed through three cycles of repeated freeze-thaw (-80°C/37°C). Then, the cell lysate was centrifuged at 5000 g for 10 minutes, followed by filtration using a 0.45-μm PVDF filter (EMD Millipore,

#SE1M003M00), resulting in the collection of the first generation of adenovirus. To amplify the adenovirus, the first generation was seeded into fresh HEK293A cells for 3 days. Subsequently, the cells were harvested and lysed as described above to collect the second generation of adenovirus, which can be further amplified and used to transfect target cell for gene expression.

Western blot

Cell or eVLP lysates were prepared in RIPA lysis buffer (Beyotime Biotechnology, China) containing PMSF and a protease inhibitor cocktail (MedChemExpress, China). After centrifugation, protein samples were subjected to 10% SDS-PAGE and transferred onto polyvinylidene difluoride (PVDF) membranes (Roche, Mannheim, Germany). Afterwards, the membranes were blocked in TBST (1 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.05% Tween-20) containing 5% BSA for 1 h and subsequently incubated overnight at 4°C with diluted primary antibodies against HA tag, GFP, P65, Phospho-P65, Myd88 and Actin. Information on antibodies used was given in Table S2. The band was quantified using the FluorChem FC2 system (Alpha Innotech Corporation St. Leonardo, CA, USA).

In vivo antitumor efficacy evaluation

Female C57BL/6 mice (6–8 weeks old) were purchased from China Wushi (Shanghai, China). HLA-A*0201/K^b transgenic mice were purchased from National Human Disease Animal Model Resource Center (Beijing, China), which are a well-established model for the study of HLA-A*0201 restricted epitopes and vaccine development (Lorena Passoni 2002; Gritzapis et al., 2004; Sun et al., 2014). All animal experiments were approved by the Animal Ethics Committee of Mengchao Hepatobiliary Hospital of Fujian Medical University. The subcutaneous HCC model was established by subcutaneous injection of 3×10^6 Hepa1-6 cells into the right axilla. The orthotopic HCC mouse model was established as follows: 1) the mice were intraperitoneally anesthetized with 50mg/kg of pentobarbital; 2) the skin was prepared aseptically, and the midline laparotomy was performed after the abdomen shaving; 3)

liver subcapsular inoculation with 5×10^5 Hepa1-6-luc tumor cells mixed with the matrigel plugs; 4) the abdominal muscle and skin were fully-layer sutured.

Tumor monitoring of subcutaneous HCC cancer model was performed by a single operator every two days in two dimensions using calipers. Tumor volume was calculated from the measured data as follows: $V=AB^2/2$ (A is the long diameter and B is the short diameter). When the tumor volume grew to 50-80 mm^3, it was recorded as day 0, and then the mice were randomly divided into 5 groups (n=6) to start treatment. In the experimental group, CpG-ODN (10 μl/mouse, from 100 μM stock), eVLP (200 μg/mouse), and ePAC were administered subcutaneously to each tumor-bearing mouse on day 0 day 4 and day 8, respectively. The control group was treated for the same duration with PBS injection. For the orthotopic HCC cancer model, the mice were randomly divided into 4 groups (n=6): PBS, αTIM-3 (100 μg/mouse, Leinco Technologies, USA), ePAC (200 μg/mouse), ePAC (200 μg/mouse) + αTIM-3 (100 μg/mouse) after 10 days of tumor inoculation (recorded as day 0) and then the treatment was initiated. At the end of treatment, all mice were sacrificed by cervical dislocation and the number of tumor nodules was recorded. For the subcutaneous HCC model constructed by HLA-A*0201/K^b transgenic mice, the Hepa1-6 cells were infected by adenovirus to express HBc18-27 epitope and HLA-A*0201 before subcutaneous injection. Tumor monitoring was performed every three days and tumor volume was calculated from the measured data as previously outlined. The tumor volume grew to 50-80 mm^3 was recorded as day 0, then the mice were randomly divided into three groups (n=5): PBS, αTIM-3 (100 μg/mouse) and αTIM-3 (100 μg/mouse) + ePAC (200 μg/mouse) to start treatment.

Flow cytometry

Cells were harvested by 1.5 mL tubes and washed by 300 μl PBS. Then the samples were stained with the antibodies as needed for 30 min under dark. The detailed information on antibodies including anti-CD11c-APC, anti-CD80-PE, anti-CD86-PeCy7, anti-MHC-II-PE, anti-CD3-FITC, anti-CD8-APC,

anti-CD44-PeCy7, and anti-CD62L-PerCP was given in Table S2. Ptpn2-Tetramer-PE was purchased from Xiamen University (Xiamen, China). After staining, the samples were washed two times by PBS and finally resuspended by 300 μl PBS for detection. Flow cytometry was carried out on the FACScalibur flow cytometer (BD, San Diego, USA). Data were analyzed using FlowJo software (Treestar, Inc., San Carlos, CA, USA).

Cell imaging with confocal

The lentivirus carrying DEC205-mCherry was produced by four plasmids system (pMDL: 3.3 ug, pREV: 3.3 ug, VSVg: 3.3 ug, pCDH-CMV-DEC205-mCherry: 10 ug for one 10-cm dish transfection) and purified similarly to eVLP by ultracentrifugation from cell culture medium. CHO cells were transfected by this lentivirus to express DEC205-mCherry for three days and positively selected by puromycin. After two hours co-culture with ePAC, CHO cells were washed by PBS for three times and imaged via confocal microscopy (CLSM) using an LSM 780 instrument from Germany. The nucleus was stained with DAPI (excited at 405 nm), while the ePAC with FAM modification was excited by 488 nm and mCherry was excited at 561 nm.

Enzyme-linked immunosorbent assay

The supernatant from DC2.4 cells stimulated by ePAC was collected and centrifuged at 2000 g for 10 min to remove the cell debris. Mouse IL-6 and IL-12p70 were quantified using Elisa kits (Boster Biological Technology, China) following the manufacturer’s protocols.

Immunogenicity validation by Elispot

CpG-ODN, eVLP and ePAC were injected subcutaneously in the lateral flank of C57BL/6 mice on days 0, 4 and 8, respectively. The dose usage for each mouse was similar to the experiments of in vivo antitumor efficacy evaluation. The mice were sacrificed on day 12 and the splenic T cells were harvested for ex vivo interferon (IFN)-γ ELISPOT assay. IFN-γ secretion of mouse splenic T cells were detected by

ELISPOT kit (Mabtech, 3321-4APT-10). Briefly, bone marrow derived-DCs (BMDCs) were isolated from 6-8 weeks old naive C57BL/6 mouse femurs and tibias. After removal of residual soft tissue and epiphyses, the marrow was collected by flushing the canals with PBS and centrifuged at 800g for 5 min at room temperature. The precipitated cells were lysed with 1mL Red Blood Cell Lysis Solution (Gibco) for 4 minutes, centrifuged at 800g for 5 minutes, and washed twice with PBS. At day 0, 2 million cells/well were added into a 6-well plate and cultured with 2 mL RPMI-1640 medium/well (10 ng/mL IL-4, and 20 ng/mL mGM-CSF, GenScript, China) to obtain BMDCs at 37°C with 5% CO_2. Half volume of medium was changed at day 3. At day 6, the BMDCs were pulsed with CpG-ODN, eVLP or ePAC for 48h. For ELISPOT assay, 2×10^4 stimulated BMDCs were co-incubated with 2×10^5 splenic T cells in a multiscreen 96-well filtration plate (Mabtech, 3321-4APT-2) at 37°C with 5% CO_2 for another 48h. BMDCs pulsed with PBS were used as the negative control. Then, the plates were washed and subsequently incubated with detection antibody (R4-6A2-biotin, 1 μg/mL, 100 μl/well) for 2 hours at room temperature. Afterwards, the plates were washed again and then incubated with Streptavidin ALP (1:1000 dilution, 100 μl per well) for 1 hour at room temperature. Subsequently, 3, 3', 5, 5'-Tetramethylbenzidine (TMB) substrate solution was added to each well and incubated for 4-8 min at room temperature before adding deionized water to stop the reaction. Finally, IFN-γ spot-forming cells were imaged and analyzed by ELISPOT Analysis System (AT-Spot-2200, Beijing Antai Yongxin Medical Technology, China).

In vitro Cytotoxicity Assays

The cell culture medium from different co-culture system was collected and centrifuged at 250 g for 10 min. The supernatant was further diluted for LDH detection according to the product manual (MK401, Takara). Briefly, 100 μl sample was transferred into a 96-well flat bottom plate following 100 μl reaction mixture. Then, the plate was incubated at room temperature for 30 min protected from light. Finally, the absorbance of the samples at 490nm was measured. The cytotoxicity was calculated by the equation:

Cytotoxicity = (Absorbance (sample) - Absorbance (low control)) / (Absorbance (high control) - Absorbance (low control)) * 100%

HE and Immunohistochemistry staining

HE staining was performed according to routine protocols. Briefly, after finishing deparaffinization and rehydration, the organ sections were stained 5 min with hematoxylin solution (G1004, Servicebio, China), followed by 5 dips in 1% acid ethanol (1% HCl in 75% ethanol) and then rinsed in distilled water. Then the sections were stained with eosin solution (G1001, Servicebio, China) for 3 minutes and followed by dehydration with graded alcohol and then clearing in xylene. The HE-stained slides were digitized, and the crop images were collected.

For immunohistochemistry staining, the paraffin-embedded tumor sections were mounted on slides, dewaxed in xylene, and rehydrated in graded alcohol washes. Afterwards, the slides were heated by microwave in 0.01 mol/L trisodium citrate buffer for antigen retrieval. Then, 5% BSA was used to block nonspecific bonding sites for 30 minutes and 3% H_2O_2 was used to suppress endogenous peroxidase activity. The slides were then incubated with primary mouse antibody (CD4 and CD8, detailed information from Table S2) overnight at 4°C and washed with Tris-buffered saline (TBS) before incubation with labeled polymer horseradish peroxidase rabbit antibody for 30 minutes. Counterstaining was performed with hematoxylin. Finally, the slides were dehydrated through ascending alcohols to xylene and mounted to take photos. The index of CD4 and CD8 was given as the ratio between positive nuclei and total number of nuclei per visual field. Three visual fields per sample were randomly selected for analysis.

Immunofluorescence staining

The primary antibodies for the immune inhibitory receptor panel included anti-CD8 (ab217344, Abcam), anti-PD-1 (ab214421, Abcam), anti-TIM-3 (ab241332, Abcam), and anti-CTLA-4 (ab237712, Abcam). Nuclei were highlighted using DAPI. The

primary antibodies were added after successful blocking and incubated for one hour at room temperature, followed by secondary antibody incubation for 30 minutes at room temperature. The images with the final fluorescent were taken by the PhenoImager® HT instrument (Akoya Biosciences, USA)

Data analysis

Statistical analysis of data was analyzed through one-way or two-way analysis of variance (ANOVA) for comparison among multiple groups. *$p < 0.05$ was set as statistically significant. **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$. Results are presented as mean ± standard error of the mean (SEM) at least three experiments by GraphPad Prism software (San Diego, USA).

Data availability

The data used to generate the results are shown in Figures and Supplementary Figures are available as supplementary information. Source data are provided with this paper.

Acknowledgements

The studies involving human-derived blood were conducted in compliance with ethical regulations and approved by the Ethics Review Committee of Mengchao Hepatobiliary Hospital of Fujian Medical University (KESHEN 2021_100_02). All animal procedures were conducted according to the “National animal management regulations of China” and approved by the Animal Ethics Committee of Mengchao Hepatobiliary Hospital of Fujian Medical University. This work was supported by the National Natural Science Foundation of China (no. 82202027 and U22A20328); the Major Research Projects for Young and Middle-aged Talent of Fujian Provincial Health Commission (2022ZQNZD014), the Young and Middle-aged Talent Training Project of Fujian Provincial Health Commission (no. 2022GGA049); the Scientific Foundation of Fujian Province (no. 2023J06049 and 2022J011279); the Startup Fund for Scientific Research, Fujian Medical University (no. 2021QH1157).

Author contributions

R.T., Y.Z., Z.C., and X.L. designed the study. R.T., L.G., T.W., T.C., H.Y., H.Y., and F.L. conducted the experiments. R.T., L.G., T.C., Z.C., and X.L. analyzed and discussed data. R.T., Z.C., and X.L. wrote and reviewed the manuscript. Z.C., and X.L. supervised the study. All authors read and approved the final manuscript.

Declaration of interests

The authors declare no competing interests.

Keywords

Neoantigen, Virus-like particle, PEG10, CpG-ODN, TIM-3 antibody

References

Abed M, Verschueren E, Budayeva H, Liu P, Kirkpatrick DS, Reja R, Kummerfeld SK, Webster JD, Gierke S, Reichelt M, Anderson KR, Newman RJ, Roose-Girma M, Modrusan Z, Pektas H, Maltepe E, Newton K and Dixit VM. 2019. The Gag protein PEG10 binds to RNA and regulates trophoblast stem cell lineage specification. *PLoS One* **14**:e0214110. 10.1371/journal.pone.0214110

Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y and Tamada K. 2018. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. *Nat Biotechnol* **36**:346-351. 10.1038/nbt.4086

An M, Raguram A, Du SW, Banskota S, Davis JR, Newby GA, Chen PZ, Palczewski K and Liu DR. 2024. Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. *Nat Biotechnol* 10.1038/s41587-023-02078-y

Ashley J, Cordy B, Lucia D, Fradkin LG, Budnik V and Thomson T. 2018. Retrovirus-like Gag

747 Protein Arc1 Binds RNA and Traffics across Synaptic Boutons. *Cell* **172**:262-274 e211.
748 10.1016/j.cell.2017.12.022
749 Banskota S, Raguram A, Suh S, Du SW, Davis JR, Choi EH, Wang X, Nielsen SC, Newby GA,
750 Randolph PB, Osborn MJ, Musunuru K, Palczewski K and Liu DR. 2022. Engineered
751 virus-like particles for efficient in vivo delivery of therapeutic proteins. *Cell*
752 **185**:250-265. 10.1016/j.cell.2021.12.021
753 Boker KO, Lemus-Diaz N, Rinaldi Ferreira R, Schiller L, Schneider S and Gruber J. 2018. The
754 Impact of the CD9 Tetraspanin on Lentivirus Infectivity and Exosome Secretion. *Mol*
755 *Ther* **26**:634-647. 10.1016/j.ymthe.2017.11.008
756 Cai Y, Bak RO and Mikkelsen JG. 2014. Targeted genome editing by lentiviral protein
757 transduction of zinc-finger and TAL-effector nucleases. *Elife* **3**:e01911.
758 10.7554/eLife.01911
759 Cai Z, Su X, Qiu L, Li Z, Li X, Dong X, Wei F, Zhou Y, Luo L, Chen G, Chen H, Wang Y, Zeng
760 Y and Liu X. 2021. Personalized neoantigen vaccine prevents postoperative
761 recurrence in hepatocellular carcinoma patients with vascular invasion. *Mol Cancer*
762 **20**:1-13. 10.1186/s12943-021-01467-8
763 Chen H, Li Z, Qiu L, Dong X, Chen G, Shi Y, Cai L, Liu W, Ye H, Zhou Y, Ouyang J, Cai Z and
764 Liu X. 2022. Personalized neoantigen vaccine combined with PD-1 blockade
765 increases CD8(+) tissue-resident memory T-cell infiltration in preclinical hepatocellular
766 carcinoma models. *J Immunother Cancer* **10**:e004389. 10.1136/jitc-2021-004389
767 Coffman RL, Sher A and Seder RA. 2010. Vaccine adjuvants: putting innate immunity to work.
768 *Immunity* **33**:492-503. 10.1016/j.immuni.2010.10.002

769 Gritzapis AD, Sotiriadou NN, Papamichail M and Baxevanis CN. 2004. Generation of human
770 tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from
771 eluates of human primary breast and ovarian tumors. *Cancer Immunol Immunother*
772 **53**:1027-1040. 10.1007/s00262-004-0541-9
773 Guo Y, Xie Y, Gao M, Zhao Y, Franco F, Wenes M, Siddiqui I, Bevilacqua A, Wang H, Yang H,
774 Feng B, Xie X, Sabatel CM, Tschumi B, Chaiboonchoe A, Wang Y, Li W, Xiao W, Held
775 W, Romero P, Ho P-C and Tang L. 2021. Metabolic reprogramming of terminally
776 exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. *Nature Immunology*
777 **22**:746-756. 10.1038/s41590-021-00940-2
778 Hamilton JR, Chen E, Perez BS, Sandoval Espinoza CR, Kang MH, Trinidad M, Ngo W and
779 Doudna JA. 2024. In vivo human T cell engineering with enveloped delivery vehicles.
780 *Nat Biotechnol* 10.1038/s41587-023-02085-z
781 Hamilton JR, Tsuchida CA, Nguyen DN, Shy BR, McGarrigle ER, Sandoval Espinoza CR, Carr
782 D, Blaeschke F, Marson A and Doudna JA. 2021. Targeted delivery of CRISPR-Cas9
783 and transgenes enables complex immune cell engineering. *Cell Rep* **35**:109207.
784 10.1016/j.celrep.2021.109207
785 Kaczmarczyk SJ, Sitaraman K, Young HA, Hughes SH and Chatterjee DK. 2011. Protein
786 delivery using engineered virus-like particles. *Proc Natl Acad Sci U S A*
787 **108**:16998-17003. 10.1073/pnas.1101874108
788 Klamp T, Schumacher J, Huber G, Kuhne C, Meissner U, Selmi A, Hiller T, Kreiter S, Markl J,
789 Tureci O and Sahin U. 2011. Highly specific auto-antibodies against claudin-18
790 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and

791 inhibit the growth of lung metastases. *Cancer Res* **71**:516-527.
792 10.1158/0008-5472.CAN-10-2292
793 Lahoud MH, Ahmet F, Zhang JG, Meuter S, Policheni AN, Kitsoulis S, Lee CN, O'Keeffe M,
794 Sullivan LC, Brooks AG, Berry R, Rossjohn J, Mintern JD, Vega-Ramos J, Villadangos
795 JA, Nicola NA, Nussenzweig MC, Stacey KJ, Shortman K, Heath WR and Caminschi I.
796 2012. DEC-205 is a cell surface receptor for CpG oligonucleotides. *Proc Natl Acad Sci*
797 *U S A* **109**:16270-16275. 10.1073/pnas.1208796109
798 Li J, Panetta F, O'Keeffe M, Leal Rojas IM, Radford KJ, Zhang JG, Fernandez-Ruiz D, Davey
799 GM, Gully BS, Tullett KM, Rossjohn J, Berry R, Lee CN, Lahoud MH, Heath WR and
800 Caminschi I. 2021. Elucidating the Motif for CpG Oligonucleotide Binding to the
801 Dendritic Cell Receptor DEC-205 Leads to Improved Adjuvants for Liver-Resident
802 Memory. *J Immunol* **207**:1836-1847. 10.4049/jimmunol.2001153
803 Li J, Sun Y, Jia T, Zhang R, Zhang K and Wang L. 2014. Messenger RNA vaccine based on
804 recombinant MS2 virus-like particles against prostate cancer. *Int J Cancer*
805 **134**:1683-1694. 10.1002/ijc.28482
806 Li L, Goedegebuure SP and Gillanders WE. 2017. Preclinical and clinical development of
807 neoantigen vaccines. *Ann Oncol* **28**:xii11-xii17. 10.1093/annonc/mdx681
808 Lin X, Tang S, Guo Y, Tang R, Li Z, Pan X, Chen G, Qiu L, Dong X, Zhang L, Liu X, Cai Z and
809 Xie B. 2024. Personalized neoantigen vaccine enhances the therapeutic efficacy of
810 bevacizumab and anti-PD-1 antibody in advanced non-small cell lung cancer. *Cancer*
811 *Immunol Immunother* **73**:26. 10.1007/s00262-023-03598-x
812 Lorena Passoni AS, Carla Bertazzoli, Barbara Gallo, Addolorata M. L. Coluccia, Francois A.

813 Lemonnier, Konstadinos Kosmatopoulos, and Carlo Gambacorti-Passerini. 2002. ALK
814 as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1–
815 restricted CD81 T-cell epitopes. *Blood* **99**:2100-2106. DOI: 10.1182/blood.v99.6.2100
816 Lux A, Beil C, Majety M, Barron S, Gallione CJ, Kuhn HM, Berg JN, Kioschis P, Marchuk DA
817 and Hafner M. 2005. Human retroviral gag- and gag-pol-like proteins interact with the
818 transforming growth factor-beta receptor activin receptor-like kinase 1. *J Biol Chem*
819 **280**:8482-8493. 10.1074/jbc.M409197200
820 Lynn GM, Sedlik C, Baharom F, Zhu Y, Ramirez-Valdez RA, Coble VL, Tobin K, Nichols SR,
821 Itzkowitz Y, Zaidi N, Gammon JM, Blobel NJ, Denizeau J, de la Rochere P, Francica
822 BJ, Decker B, Maciejewski M, Cheung J, Yamane H, Smelkinson MG, Francica JR,
823 Laga R, Bernstock JD, Seymour LW, Drake CG, Jewell CM, Lantz O, Piaggio E,
824 Ishizuka AS and Seder RA. 2020. Peptide-TLR-7/8a conjugate vaccines chemically
825 programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor
826 antigens. *Nat Biotechnol* **38**:320-332. 10.1038/s41587-019-0390-x
827 Mandelboim O VE, Fridkin M, Katz-Hillel A, Feldman M, Berke G, Eisenbach L. 1995.
828 Regression of established murine carcinoma metastases following vaccination with
829 tumour-associated antigen peptides. *Nat Med* **1**:1179-1183.
830 Mangeot PE, Risson V, Fusil F, Marnef A, Laurent E, Blin J, Mournetas V, Massourides E,
831 Sohier TJM, Corbin A, Aube F, Teixeira M, Pinset C, Schaeffer L, Legube G, Cosset
832 FL, Verhoeyen E, Ohlmann T and Ricci EP. 2019. Genome editing in primary cells and
833 in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins.
834 *Nat Commun* **10**:45. 10.1038/s41467-018-07845-z

835 Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ and Ahmadian G.
836 2021. Virus-like particles: preparation, immunogenicity and their roles as
837 nanovaccines and drug nanocarriers. *J Nanobiotechnology* **19**:59.
838 10.1186/s12951-021-00806-7
839 Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A,
840 Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J,
841 Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI,
842 Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G,
843 Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N and Wu CJ.
844 2017. An immunogenic personal neoantigen vaccine for patients with melanoma.
845 *Nature* **547**:217-221. 10.1038/nature22991
846 Pandya NJ, Wang C, Costa V, Lopatta P, Meier S, Zampeta FI, Punt AM, Mientjes E, Grossen
847 P, Distler T, Tzouros M, Marti Y, Banfai B, Patsch C, Rasmussen S, Hoener M,
848 Berrera M, Kremer T, Dunkley T, Ebeling M, Distel B, Elgersma Y and Jagasia R.
849 2021. Secreted retrovirus-like GAG-domain-containing protein PEG10 is regulated by
850 UBE3A and is involved in Angelman syndrome pathophysiology. *Cell Rep Med*
851 **2**:100360. 10.1016/j.xcrm.2021.100360
852 Pastuzyn ED, Day CE, Kearns RB, Kyrke-Smith M, Taibi AV, McCormick J, Yoder N, Belnap
853 DM, Erlendsson S, Morado DR, Briggs JAG, Feschotte C and Shepherd JD. 2018.
854 The Neuronal Gene Arc Encodes a Repurposed Retrotransposon Gag Protein that
855 Mediates Intercellular RNA Transfer. *Cell* **172**:275-288 e218.
856 10.1016/j.cell.2017.12.024

857 Raguram A BS, Liu DR. 2022. Therapeutic in vivo delivery of gene editing agents. *Cell*
858 **185**:2806-2827. 10.1016/j.cell.2022.03.045
859 Roldão A MM, Castilho LR, Carrondo MJ, Alves PM. 2010. Virus-like particles in vaccine
860 development. *Expert Rev Vaccines* **9**:1149-1176. DOI: 10.1586/erv.10.115
861 Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, Löwer M, Bukur V, Tadmor AD,
862 Luxemburger U, Schrörs B, Omokoko T and Vormehr M. 2017. Personalized RNA
863 mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
864 *Nature* **547**:222-226. 10.1038/nature23003
865 Schumacher TN, Scheper W and Kvistborg P. 2019. Cancer Neoantigens. *Annu Rev Immunol*
866 **37**:173-200. 10.1146/annurev-immunol-042617-053402
867 Segel M, Lash B, Song J, Ladha A, Liu CC, Jin X, Mekhedov SL, Macrae RK, Koonin EV and F
868 Z. 2021. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can
869 be pseudotyped for mRNA delivery. *Science* **373**:882-889.
870 Silva DA, Yu S, Ulge UY, Spangler JB, Jude KM, Labao-Almeida C, Ali LR, Quijano-Rubio A,
871 Ruterbusch M, Leung I, Biary T, Crowley SJ, Marcos E, Walkey CD, Weitzner BD,
872 Pardo-Avila F, Castellanos J, Carter L, Stewart L, Riddell SR, Pepper M, Bernardes
873 GJL, Dougan M, Garcia KC and Baker D. 2019. De novo design of potent and
874 selective mimics of IL-2 and IL-15. *Nature* **565**:186-191. 10.1038/s41586-018-0830-7
875 Sun L, Zhang Y, Zhao B, Deng M, Liu J, Li X, Hou J, Gui M, Zhang S, Li X, Gao GF and Meng
876 S. 2014. A new unconventional HLA-A2-restricted epitope from HBV core protein
877 elicits antiviral cytotoxic T lymphocytes. *Protein Cell* **5**:317-327.
878 10.1007/s13238-014-0041-4

879 Sundquist WI and Krausslich HG. 2012. HIV-1 assembly, budding, and maturation. *Cold*
880 *Spring Harb Perspect Med* **2**:a006924. 10.1101/cshperspect.a006924
881 Voelkel C, Galla M, Maetzig T, Warlich E, Kuehle J, Zychlinski D, Bode J, Cantz T,
882 Schambach A and Baum C. 2010. Protein transduction from retroviral Gag precursors.
883 *Proc Natl Acad Sci U S A* **107**:7805-7810. 10.1073/pnas.0914517107
884 Wei Y LL, Gui T, Yu F, Yan L, Yao L, Zhong L, Yu W, Han B, Patel JM, Liu JF, Beier F, Levin
885 LS, Nelson C, Shao Z, Han L, Mauck RL, Tsourkas A, Ahn J, Cheng Z, Qin L. 2021.
886 Targeting cartilage EGFR pathway for osteoarthritis treatment. *Sci Transl Med*
887 **13**:eabb3946.
888 Zhao Q, Wang Y, Zhao B, Chen H, Cai Z, Zheng Y, Zeng Y, Zhang D and Liu X. 2022.
889 Neoantigen Immunotherapeutic-Gel Combined with TIM-3 Blockade Effectively
890 Restrains Orthotopic Hepatocellular Carcinoma Progression. *Nano Lett* **22**:2048-2058.
891 10.1021/acs.nanolett.1c04977
892 Zhao Y, Chen J, Andreatta M, Feng B, Xie Y-Q, Wenes M, Wang Y, Gao M, Hu X, Romero P,
893 Carmona S, Sun J, Guo Y and Tang L. 2024. IL-10-expressing CAR T cells resist
894 dysfunction and mediate durable clearance of solid tumors and metastases. *Nature*
895 *Biotechnology* 10.1038/s41587-023-02060-8
896
897
898
899
900
901
902

Figure legends

Figure 1. Designing and identifying the eVLP package system. (**A**) Schematic representation of PEG10 variants. The putative cutting site from PEG10 and GS linker were used to fuse PEG10 and eGFP together. HA tag was co-expressed in the C-terminal for subsequent identification. (**B**) The eVLP packaging process was illustrated in the schematic diagram. Plasmids from (A) were co-transfected with VSVg into HEK293T cells. eVLPs were harvested from the cell culture medium by ultracentrifugation. (**C**) The fluorescent image representing the eVLP transfected HEK293T cells (in blue) after 24h, and the positive percentage was analyzed by flow cytometry. Scale bar, 100 μm. (**D**) The cells from (C) were harvested for HA tag and eGFP detection by western blot. 20 μl from each sample was loaded to the SDS-PAGE. Lane 1: eGFP, Lane 2: gag-//-eGFP, Lane 3: gag-GS-eGFP, Lane 4: gag-//-pol-eGFP (gag domain: ~50 kD; gag-pol domain: ~120 kD; eGFP: 27 kD). (**E**) and (**F**) Comparison of the eVLP transfection efficiency under different packaging strategies by flow cytometry. The plasmid ratio between gag-pol and gag-eGFP was optimized. The total plasmids for transfection in one 10-cm dish were 19 μg. (**G**) and (**H**) Identification of the auxiliary function of VSVg during eVLP transfection. Data are presented as the mean ± SEM.

Figure 2. Envelope decoration of neoantigen-loaded eVLP. (**A**) Schematic of the decoration strategy for eVLP. DBCO-C6-NHS Ester was first anchored to eVLP under 4°C for 12h. Then, 5’-FAM-CpG-ODN-3’-Azide was added to trigger click reaction for 2h at 37°C. The CpG-ODN modified eVLP carrying antigens was named as ePAC. (**B**) Agarose gel electrophoresis of CpG-ODN modified eVLP with various DBCO-C6-NHS Ester concentration. eVLP: 200 μl per reaction, 5’-FAM-CpG-ODN-3’-Azide: 1 nmol per reaction. 20 μl sample was loaded in each lane. (**C**) The percentage of FAM positive HEK293T cells analyzed by flow

cytometry. 50 μl modified eVLP from (B) was used to transfect HEK293T cells in a 24-well plate. (**D**) and (**E**) The bonding affinity between DEC-205 expressed CHO cells and ePAC was analyzed by flow cytometry (n=3 independent replicates; one-way ANOVA). CHO cells were transfected by the plasmid pCDH-DEC-205 to transiently express DEC-205. (**F**) The confocal microscopy images showing the bonding of DEC-205 and ePAC. CHO cells were transfected by lentivirus to express DEC-205-mCherry. Scale bar, 100 μm. Data are presented as the mean ± SEM. *$p < 0.05$.

Figure 3. In vitro stimulation of DCs by ePAC. (**A**) The strategy for DC2.4 cell stimulation and detection. (**B**) The strategy for mouse-derived BMDC/T cell stimulation and Hepa1-6 co-culture. (**C**) The percentage and statistical analysis of ePAC transfection efficiency for DC2.4 cells by flow cytometry. (**D**) The percentage and statistical analysis of ePAC transfection efficiency for BMDCs by flow cytometry. (**E**) Cytokine secretion by DC2.4 cells at different time point after ePAC stimulation. (**F**) Western blot analysis of phospho-P65 and Myd88 expression at different time point after ePAC stimulation. P65 and Actin were used as loading control to calculate the fold change of p-P65 and Myd88 in different samples, respectively. P65: ~65 kDa, Myd88: ~33 kDa, Actin: 43 kDa. (**G**) and (**H**) The percentage and statistical analysis of matured DCs with CD80 and CD86 co-expression detected by flow cytometry (n=3 independent replicates; one-way ANOVA). (**I**) In vitro cytotoxicity against neoantigen-expressing Hepa1-6 cells determined by LDH assay (n=3 independent replicates; one-way ANOVA). Data are presented as the mean ± SEM. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$; ns, no significance.

Figure 4. ePAC delivery and immune activation in vivo. (**A**) and (**B**) Ex vivo fluorescence image of isolated axillary lymph nodes (n=3 mice). eVLP was incubated with Dil for 6 h and then injected subcutaneously near the axilla of mice. 24 hours later, the axillary lymph nodes were collected and photographed. Every two lymph

nodes came from one mouse. (**C**) The statistical analysis of lymph node fluorescence intensity from (B) (n=3 mice; one-way ANOVA). (**D**) and (**E**) The percentage and statistical analysis of Dil positive DC cells in the lymph nodes detected by flow cytometry (n=3 mice; one-way ANOVA). (**F**) Schematic diagram of the vaccination protocol for C57BL/6 mice. (**G**) and (**H**) The percentage and statistical analysis of MHC expression level in the lymph nodes detected by flow cytometry (n=3 mice; one-way ANOVA). (**I**) and (**J**) The percentage and statistical analysis of matured DCs with CD80 and CD86 co-expression in the lymph nodes detected by flow cytometry (n=3 mice; one-way ANOVA). (**K**) and (**L**) ELISPOT assay showing neoantigen-specific reactivity of splenic T cells against Hepa1-6-derived neoantigens on day 12 after vaccination (n=3 mice; one-way ANOVA). Data are presented as the mean ± SEM. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$; ns, no significance.

Figure 5. Antitumor effect of ePAC in subcutaneous HCC model. (**A**) Schematic diagram of vaccination-associated therapy in subcutaneous HCC model (n=6 mice). C57BL/6 mice were inoculated with Hepa1-6 cells on day -10 and immunized with the indicated vaccine formulations on day 0, 4 and 8 for a total of 3 treatments. (**B**) Growth curves of the average tumor volumes in the indicated groups (n=6 mice; two-way ANOVA). (**C**) Representative images of tumors harvested from tumor-bearing mice on day 20. (**D**) and (**E**) The percentage and statistical analysis of effector memory T cells in splenic $CD8^+$ T cells detected by flow cytometry (n=6 mice; one-way ANOVA). (**F**) and (**G**) Immunohistochemical staining of $CD4^+$ and $CD8^+$ cells (brown) in the tumors collected at the day 20 and the quantitation of $CD4^+$ and $CD8^+$ cells in each field (n=3, two-way ANOVA). Scale bar: 100 μm in the lower panels. (**H**) and (**I**) The percentage and statistical analysis of activated T cells expressing 4-1BB from tumors detected by flow cytometry (n=6 mice; one-way ANOVA). (**J**) and (**K**) Representative images and the expression analysis of CD8, PD-1, TIM-3, and CTLA-4 in tumors by immunofluorescence (n=3; two-way ANOVA). Scale bar: 50 μm. Data are presented as the mean ± SEM. *$p < 0.05$, **p <

0.01, ***p < 0.001, ****p < 0.0001; ns, no significance.

Figure 6. Evaluation ePAC antitumor efficacy in orthotopic HCC model by αTIM-3 combination. (**A**) Schematic diagram of vaccination-associated therapy in orthotopic HCC model (n=6 mice). (**B**) Tumor burden monitoring of PBS, αTIM-3 alone, ePAC alone, and ePAC plus αTIM-3 treated mice by bioluminescence imaging. (**C**) The photographs and H&E staining of tumor-bearing livers collected from mice after different treatments as indicated. "T" represents tumor tissues, "L" represents liver tissues, and there is the clear boundary with non-tumor sites. (**D-I**) Flow cytometry analysis of effector memory T cells in splenic $CD8^+$ T cells (D and G), $CD8^+$ T cell infiltration in the tumors (E and H), and $Ptpn2_{376-384}$: H-$2K^b$ specific $CD8^+$ T cells in tumor infiltrating $CD8^+$ T cells (F and I). n=6 mice; one-way ANOVA. Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Figure 7. HBc18-27-specific immune response induced by eVLP-based vaccine. (**A**) The strategy for T cell stimulation and tumor cell killing. (**B**) The analysis of stimulated $CD8^+$ T cells detected by flow cytometry (n=3; one-way ANOVA). PBMCs were first activated by anti-CD3 and anti-CD28 for 2 days and then co-cultured with ePAC stimulated DCs for three times. (**C**) Tumor killing assay of HepG2(2.15) cells visualized by microscopy. (**D**) In vitro cytotoxicity analysis after PBMC and HepG2 co-culture (n=3; two-way ANOVA). The supernatant from different time points were harvested for LDH assay. Scale bar, 100 μm. (**E**) Schematic diagram of vaccination-associated therapy in subcutaneous HCC model constructed by HLA-A*0201 transgenic mice (n=5 mice). (**F**) Growth curves of the average tumor volumes in the indicated groups (n=5 mice; two-way ANOVA). (**G**) Representative images of tumors harvested from tumor-bearing mice on day 16. (**H-K**) Flow cytometry analysis of $CD8^+$ T cell infiltration in the tumors (H and J) and the activated level of $CD8^+$ T cells in tumors (I and K). n=6 mice; one-way ANOVA. Data are presented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p <

1023 0.0001.


A
gag-//-eGFP
gag
//
eGFP
gag-GS-eGFP
gag
GS
eGFP
gag-//-pol-eGFP
gag
//
pol
eGFP
// putative cutting site
GS GS linker
HA tag


B
PEG10
(gag)
+
POI
or
PEG10
(gag+pol)
+
POI
+
VSVg
Plasmids for
transfection
Producer cells (HEK293T)
eVLP harvest
endogenous VLP
(eVLP)
PEG10
Cell membrane
VSVg
POI


C
eGFP
+
VSVg
gag-//-eGFP
+
VSVg
gag-GS-eGFP
+
VSVg
gag-//-pol-eGFP
+
VSVg
0%
85.2%
90.1%
68.4%
eGFP
SSC


E
ctrl
0.12%
0:16:3
80.9%
1:15:3
63.6%
2:14:3
79.4%
4:12:3
59.2%
8:8:3
35.2%
16:0:3
0.1%
eGFP
SSC


F
% of postive cells
gag-pol (µg) - 0 1 2 4 8 16
gag-eGFP (µg) - 16 15 14 12 8 0
VSVg (µg) - 3 3 3 3 3 3


D
1 2 3 4
180
130
100
70
55
40
35
25
(kDa)
IB: HA tag
IB: eGFP
1. eGFP + VSVg
2. gag-//-eGFP + VSVg
3. gag-GS-eGFP + VSVg
4. gag-//-pol-eGFP + VSVg


G
ctrl
gag-pol
gag-eGFP
gag-pol
gag-eGFP
+ VSVg
P2
16.4%
73.5%
eGFP
SSC


H
% of postive cells
gag-pol - + +
gag-eGFP - + +
VSVg - - +


A
PEG10
Cell membrane
VSVg
Antigens
eVLP
DBCO-C6-NHS Ester
4°C, 12h
TCCATGACGTTCCTGACGTT
1826
5' FAM-CpG-ODN-3' Azide
37°C, 2h
CpG-ODN
eVLP + Antigens + CpG-ODN
(ePAC)
B
eVLP + + + +
DBCO 0 3.5 nmol 7 nmol 14nmol
CpG + + + +
C
eVLP + + + +
DBCO 0 3.5 nmol 7 nmol 14nmol
CpG + + + +
0.24%
99.8%
96.5%
84.6%
SSC
FAM
D
CHO: DEC-205
ePAC
ePAC
CHO
eVLP + CpG
eVLP
FAM
E
% of postive cells
P = 0.0035
eVLP
eVLP + CpG
ePAC
ePAC
CHO
CHO: DEC-205
F
DAPI
mCherry
CpG-ODN
Overlay
CHO
CHO: DEC-205-mCherry
100 um


A
DC2.4
supernatant (6 h/24 h)
IL-6/IL-12
cell lysate (6 h/24 h)
P65/Myd88
B
incubation for 2 days
DCs (IL-4/GM-CSF)
3 times stimulation
spleenic T cells
2 days co-culture
Hepa1-6
3 days co-culture
LDH
C
eVLP
eVLP + CpG
ePAC
0.21%
16.7%
99.9%
SSC
FAM
% of postive cells
D
0.61%
21.9%
43.4%
E
IL-6 (pg/ml)
IL-12p70 (pg/ml)
ctrl
CpG
eVLP
ePAC
6h
24h
G
9.38%
19.9%
12.7%
23.7%
CD80
CD86
F
Marker
p-P65
P65
Myd88
Actin
(kDa)
fold: 0.15 0.22 0.34 0.79
fold: 0.05 0.18 0.67 0.64
fold: 0.13 0.49 0.37 0.63
fold: 0.17 0.24 0.51 0.72
H
P < 0.0001
P = 0.0012
P < 0.0001
CD80+ CD86+ in CD11c+ cells (%)
I
P < 0.0001
P < 0.0001
P < 0.0001
ns
Cytotoxicity (%)
Peptides + CpG


A
day 0
day 2
injection
sacrifice
B
PBS
DiI
DiI + eVLP
DiI + ePAC
high
low
C
P = 0.0003
ns
Lymph node florescence
200
150
100
50
0
PBS
DiI
DiI + eVLP
DiI + ePAC
D
CD11c⁺ cell
DiI
4.99%
DiI + eVLP
9.68%
DiI + ePAC
12.50%
SSC
DiI
E
P = 0.0037
P = 0.0391
DiI⁺ in CD11c⁺ cells (%)
15
12
9
6
3
DiI
DiI + eVLP
DiI + ePAC
F
day 0
day 4
day 8
day 12
1st vaccination
2nd vaccination
3rd vaccination
sacrifice
G
ctrl
37.7%
CpG
58.0%
eVLP
49.4%
ePAC
63.0%
MHC II
CD11c
H
P = 0.0012
ns
P = 0.0093
MHC II⁺ in CD11c⁺ cells (%)
70
60
50
40
30
ctrl
CpG
eVLP
ePAC
I
ctrl
8.6%
CpG
18.4%
eVLP
16.1%
ePAC
24.7%
CD80
CD86
J
P < 0.0001
ns
P = 0.0023
CD80⁺ CD86⁺ in CD11c⁺ cells (%)
30
25
20
15
10
5
ctrl
CpG
eVLP
ePAC
K
ctrl
CpG
eVLP
ePAC
L
P < 0.0001
P < 0.0001
P = 0.0011
IFN-γ spots/10⁵ T cells
200
150
100
50
0
ctrl
CpG
eVLP
ePAC


A
Subcutaneous HCC model
3x10⁶/200 µl
Hepa 1-6 cells
Day post treatment
-10
0
4
8
20
Vaccination
B
PBS
CpG
eVLP
eVLP + CpG
ePAC
Tumor volume/mm³
Day post treatment
P < 0.0001
P < 0.0001
P = 0.0002
C
PBS
CpG
eVLP
eVLP + CpG
ePAC
D
PBS
CpG
eVLP
eVLP + CpG
ePAC
9.17%
23.1%
14.6%
25.8%
34.7%
CD44
CD62L
E
Effctor memory T cells (%)
P < 0.0001
P < 0.0001
P < 0.0001
P = 0.0005
F
CD4: PBS
CpG
eVLP
eVLP + CpG
ePAC
CD8: PBS
CpG
eVLP
eVLP + CpG
ePAC
G
Number of cells in each field
P < 0.0001
P = 0.0003
P = 0.0040
P = 0.0173
P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001
H
PBS
CpG
eVLP
eVLP + CpG
ePAC
7.0%
18.4%
9.94%
41.1%
64.9%
4-1BB
CD8
I
4-1BB⁺ in CD8⁺ T cells from tumor (%)
P < 0.0001
P < 0.0001
P < 0.0001
P = 0.0003
J
PBS: CD8 PD-1 TIM-3 CTLA-4 DAPI
ePAC: CD8 PD-1 TIM-3 CTLA-4 DAPI
Merge
CD8
PD-1
TIM-3
CTLA-4
K
Number of cells in each field
ns
P < 0.0001
ns
PD-1
TIM-3
CTLA-4
PBS
ePAC


A
Orthotopic HCC model
5x10⁵ Hepa 1-6 cells with LUC
Day post treatment
-10
0
4
8
14
28
Treatment
Bioluminescence imaging
B
PBS
αTIM-3
ePAC
ePAC + αTIM-3
day0
day14
day21
day28
C
PBS
αTIM-3
ePAC
ePAC + αTIM-3
T
L
D
PBS
αTIM-3
ePAC
ePAC + αTIM-3
7.86%
12.3%
13.4%
17.1%
CD44
CD62L
E
36.5%
42.7%
42.6%
57.3%
Count
CD8
F
1.2%
0.7%
4.2%
10.7%
Ptpn2-Tetramer
CD8
G
Effctor memory T cells (%)
P = 0.0004
P = 0.0269
P = 0.0290
PBS
αTIM-3
ePAC
ePAC + αTIM-3
H
CD8⁺ in CD3⁺ T cells (%)
P = 0.0001
P < 0.0001
P = 0.0003
I
Ptpn2-Tetramer in CD8⁺ T cells (%)
P = 0.0002
P < 0.0001
P = 0.0022


A
incubation for 2 days
DCs (IL-4/GM-CSF)
3 times stimulation
T cells
2 days co-culture
HepG2
3 days co-culture
LDH
B
ePAC
eVLP
ctrl
4-1BB
4-1BB+ in CD8+ T cells (%)
P = 0.0022
P = 0.0216
ctrl
eVLP
ePAC
C
0 day
1 day
2 day
3 day
HepG2 ctrl
HepG2 eVLP
HepG2 ePAC
D
HepG2: ctrl
HepG2: eVLP
HepG2: ePAC
Cytotoxicity (%)
P < 0.0001
P < 0.0001
Time Post Co-culture (h)
E
3x10^6/200 µl Hepa 1-6 cells with HBc18-27 and HLA-A*0201
Day post treatment
Treatment
F
PBS
αTIM-3
αTIM-3 + ePAC
Tumor volume/mm3
P < 0.0001
P < 0.0001
Day post treatment
G
PBS
αTIM-3
αTIM-3 + ePAC
H
PBS
αTIM-3
αTIM-3 + ePAC
FSC
8.79%
11.5%
16.2%
I
4-1BB
CD8
1.00%
2.19%
15.5%
J
CD8+ in tumor cells (%)
P < 0.0001
P = 0.0002
PBS
αTIM-3
αTIM-3 + ePAC
K
4-1BB+ in CD8+ T cells (%)
P < 0.0001
P = 0.0006
PBS
αTIM-3
αTIM-3 + ePAC